Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
-
YPrime Appoints Lindsay Daniel as Chief Human Resources Officer
-
Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting
-
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
-
Indy 500 Coverage Returns to TuneIn on May 14
-
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
-
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
-
One in Three Consumers Victimized by Fraud on Gig Economy Platforms
-
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
-
Plug Receives $1.66 Billion Conditional Commitment Loan Guarantee From Department of Energy for Green Hydrogen Development Pipeline
-
Mondelēz International Showcases Sweet Collaborations & Omnichannel Expertise at Sweets & Snacks Expo
-
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
-
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
-
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
-
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
-
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
-
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
-
Northann Corp. Announces Strategic Partnership with Adornus Cabinetry
-
Freshworks to Participate in Upcoming Investor Conferences
-
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
-
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
-
VelocityEHS Earns 5 AI Patents and Publishes in Nature
-
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
-
Global Technologies, Ltd. Announces Its Financial Results for the Quarter Ended March 31, 2024 and the Company’s Strategic Business Transition
-
Net Asset Value(s)
-
Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter
-
DSV, 1108 - SHARE BUYBACK IN DSV A/S
-
Entourage Health to Hold First Quarter 2024 Financial Results Call on May 28
-
NowVertical Welcomes David Doritty as Independent Director
-
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
-
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
-
Tavros Therapeutics Achieves Two Milestone Payments in its Collaboration with Vividion Therapeutics
-
Kroma Announces Spectrum’s Launch Alongside Expansion Plans
-
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
-
MiNK Reports First Quarter 2024 Results
-
Alimera Sciences Reports First Quarter 2024 Results
-
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
-
ETFS Capital Calls on WisdomTree to Stop Fighting Stockholders and Run a Strategic Process
-
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
-
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
-
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
-
FitLife Brands Announces First Quarter 2024 Results
-
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
-
HealthEquity Closes Acquisition of BenefitWallet HSA Portfolio
-
Batteh Named Saia’s Chief Financial Officer
-
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
-
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
-
Tavros Therapeutics Achieves Two Milestone Payments in its Collaboration with Vividion Therapeutics
-
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
-
nCino Announces Timing of its First Quarter Fiscal Year 2025 Financial Results Conference Call
